Abstract
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.
Funding Information
  • National Cancer Institute of the National Institutes of Health (P50CA090440)
  • American Cancer Society Research Scholar Award (RSG TBG - 132939)
  • The University of Pittsburgh Institute for Precision Medicine (No number)
  • Libby’s Lungs (No number)
  • We Wish Foundation (No number)
  • National Cancer Institute of the National Institutes of Health (P30CA047904)
  • National Cancer Institute of the National Institutes of Health (R01 CA244270-01A1)
  • U.S. Department of Defense (W81XWH-22-1-0350)

This publication has 114 references indexed in Scilit: